Answers are grounded in this paper and cite their sources.
This article reviews safety aspects of JAK inhibitors in rheumatoid arthritis, indicating practical implications for treatment.
Janus kinase inhibitors have emerged as highly effective therapies, gaining a prominent role in rheumatoid arthritis treatment. However, by inhibiting multiple cytokine effector pathways, these agents have also raised concerns regarding their safety profile. This article aims to provide an updated overview of the main safety aspects of JAK inhibitors, with a particular focus on their use in RA.
No takes yet. Share an insight, caveat, or question.
Karina Rossi Bonfiglioli (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: